---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/100000000798192.md"
description: "📢 𝐉𝐔𝐒𝐓 𝐈𝐍: EU Approves Novo Nordisk's Oral Wegovy for Obesity Treatment - $Novo Nordisk AS(NVO.US) $Hims & Hers Health(HIMS.US) $Eli Lilly(LLY.US) 👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤  𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 approves 𝐨𝐫𝐚𝐥 𝐖𝐞𝐠𝐨𝐯𝐲 𝟐𝟓 𝐦𝐠.➤  Approval covers adults with 𝐨𝐛𝐞𝐬𝐢𝐭𝐲 or overweight with comorbidities.➤  Oral Wegovy becomes Novo Nordisk's 𝐟𝐢𝐟𝐭𝐡 regulatory approval globally.➤  OASIS 4 trial showed approximately 𝐒𝟕% mean weight loss over 64 weeks.➤  Placebo group recorded approximately 𝐒𝟑% mean weight loss.➤  Around 𝐨𝐧𝐞 𝐢𝐧 𝐭𝐡𝐫𝐞𝐞 participants lost 𝐒𝟐𝟎% or more body weight.➤  EU also approved 𝐖𝐞𝐠𝐨𝐯𝐲 𝟕.𝟐 𝐦𝐠 single-dose injection pen.➤  Novo Nordisk says the injection delivers approximately 𝐒𝟐𝟏% weight loss.➤  Company plans additional global launches in 𝐭𝐡𝐞 𝐬𝐞𝐜𝐨𝐧𝐝 𝐡𝐚𝐥𝐟 𝐨𝐟 𝟐𝟎𝟐𝟔.👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:𝐌𝐢𝐤𝐞 𝐃𝐨𝐮𝐬𝐭𝐝𝐚𝐫, president and CEO of Novo Nordisk:"For many people, a tablet may be a simpler and more acceptable way to start and continue treatment.""
datetime: "2026-07-15T16:25:51.000Z"
locales:
  - [en](https://longbridge.com/en/topics/100000000798192.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/100000000798192.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/100000000798192.md)
author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)"
generator: "portal-rs"
---

# 📢 𝐉𝐔𝐒𝐓 𝐈𝐍: EU Approves Novo Nordisk's Oral Wegovy …


### Related Stocks

- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [HIMS.US](https://longbridge.com/en/quote/HIMS.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**